

UNCLASSIFIED

AD NUMBER
ADB244889
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Sep 98. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Fort Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, 26 Aug 2002

THIS PAGE IS UNCLASSIFIED

AD_____

GRANT NUMBER DAMD17-97-1-7076

TITLE: Combinatorial Synthesis for the Expedited Discovery of Novel Selective Antiestrogens for Breast Cancer Prevention and Therapy

PRINCIPAL INVESTIGATOR: John A. Katzenellenbogen, Ph.D.

CONTRACTING ORGANIZATION: University of Illinois
Champaign, Illinois 61820

REPORT DATE: September 1998

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Sep 98). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 4

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-97-1-7076

Contractor: University of Illinois

Location of Limited Rights Data (Pages): 2-20

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Patricia C. Hodson

6/4/99

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 1998	3. REPORT TYPE AND DATES COVERED Annual (1 Sep 97 - 31 Aug 98)	
4. TITLE AND SUBTITLE Combinatorial Synthesis for the Expedited Discovery of Novel Selective Antiestrogens for Breast Cancer Prevention and Therapy			5. FUNDING NUMBERS DAMD17-97-1-7076	
6. AUTHOR(S) Katzenellenbogen, John A., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Illinois Champaign, Illinois 61820			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES			19990622 045	
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Sep 98). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) We have conceived of an approach to prepare by combinatorial methods, libraries of novel ligands for the estrogen receptor, that might be useful in the treatment or prevention of breast cancer, by the creation of simple amide or five-membered ring heterocyclic core structures that display peripheral substituents (phenols, aliphatic groups, etc.) commonly found in non-steroidal estrogens. We have made good progress on the preparation of novel estrogen of the diphenyl carboxamide class, the diphenylsulfonamide class, the phenyl benzylcarboxamide and sulfonamide classes, and the pyrazole, oxazole, thiazole, and imidazole classes. Members of same class have high affinity for the estrogen receptor. Future efforts will be directed at perfecting the solid phase synthesis of the pyrazole class, which appear to be the most promising, and expanding the size of the libraries that can be prepared.				
14. SUBJECT TERMS Breast Cancer, Estrogens, Solid-Phase Synthesis, Combinatorial Chemistry			15. NUMBER OF PAGES 20	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Limited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

 In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

____ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

____ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

 In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



21 Aug 1998

PI - Signature

Date

John A. Katzenellenbogen

TABLE OF CONTENTS

<u>Section</u>	<u>Page</u>
Table of Contents	4
Introduction	5
Body	6
Conclusions	14
References	14
Appendices	17

ANNUAL REPORT: September 1, 1997 – August 31, 1998**PRINCIPAL INVESTIGATOR: John A. Katzenellenbogen****TITLE: Combinatorial Synthesis For The Expedited Discovery Of Novel Selective Antiestrogens For Breast Cancer Prevention And Therapy****ORGANIZATION: University Of Illinois****INTRODUCTION AND GOALS OF THE PROJECT**

Antiestrogens such as tamoxifen are widely used in the treatment of hormone responsive breast cancer and recently shown to be effective in breast cancer prevention¹⁻⁵. Tamoxifen, however, as well as the pure ICI antiestrogens, are not ideal agents, because they cause vaginal atrophy and menopausal hot flashes, induce osteoporosis (pure antiestrogens), and may cause endometrial and liver cancer (tamoxifen)⁶⁻¹⁴. Thus, there is a need for the development of selective antiestrogens with an improved endocrine profile for use in the treatment and prevention of breast cancer¹⁵⁻¹⁶.

Recent advances in our understanding of the molecular pharmacology of estrogens and the development of new selective antiestrogens for menopausal bone maintenance, suggest that new selective antiestrogens of this type can be discovered¹⁶⁻²⁵. Up to now, however, this search has not been approached in a systematic fashion²⁶. Furthermore, the structures of antiestrogens that have been studied to date are quite complex and their synthesis sufficiently challenging, so as not to be amenable to synthesis by solid-phase combinatorial means. Combinatorial synthesis is the fastest growing new technology in pharmaceutical chemistry, and is proving to be a highly expeditious and promising approach to new drug discovery²⁷⁻³⁵.

In preparing for this project, we analyzed the structures of many selective antiestrogens and found that they possess three common peripheral groups (a phenol, a second aromatic group, and a basic side chain) attached to various core structures. Because the core structure appears to function as a scaffold simply to hold these other appendages together, we then designed six novel core structures that will perform the same scaffold function for the peripheral groups, yet are sufficiently simple that they can be readily prepared by solid-phase combinatorial synthesis.

In this project, we proposed to prepare six novel classes of ligands for the estrogen receptor, based on four functional group so far unexplored in the antiestrogen literature: a

carboxamide, a sulfonamide, a pyrazole, and an oxazole (and related thiazole and imidazole). Solution-phase syntheses were first to be developed, and then adapted to solid-phase synthesis using an acid-labile linker attached to the common phenol function. Libraries containing 180-1200 members of these six classes were then to be prepared, and all of these compounds then to be assayed for their binding affinity for the estrogen receptor. The estrogen agonist and antagonist activity of those members with high affinity was then later to be determined in cell transfection and proliferation assays, and those with the most appropriate endocrine activity tested in a uterotrophic assay.

The combination of a novel structural insight leading to the design of new core structures for estrogen receptor ligands that can be readily prepared by combinatorial synthesis, together with a set of simple, but effective assays to establish their hormonal activity, should assist in the discovery of novel selective antiestrogens for the treatment and prevention of breast cancer.

BODY

Experimental Approach

A General Structural Description of Selective Estrogen Receptor Ligands Suggests Alternate Core Structures that Can be Prepared by Solid Phase Combinatorial Chemistry Methods

As a class, selective antiestrogens can be envisioned as having four structural components (Schemes 1 and 2): *a core structure (A)* onto which are appended three other structural elements, *a phenol (B)*, *a second aromatic group (C)* and *a basic side chain (D)*. The achievement of an appropriate balance of estrogenic vs antiestrogenic activities in each of these series of selective antiestrogens appears to involve a delicate interaction between these component parts of their structure. Curiously, whereas components **B**, **C**, and **D** are rather similar in almost all of the selective antiestrogens (cf. Scheme 1, selective antiestrogens), the central core structure **A**, which links together the other three components like a scaffold, is quite variable. This suggests that other core structures could replace this central component in selective antiestrogens.

In the original proposal we proposed to explore new antiestrogens specifically designed to have novel core structures that are readily amenable to solid phase combinatorial synthesis and which may prove to be more tissue selective and efficacious for breast cancer. As explained in Scheme 3, we identified three simple structure motifs that are found in ER ligands, around which we designed six new classes of potential ligands for the ER that are based on four new core structures (Scheme 3, right column). We anticipated that these four core structures—a carboxamide, a sulfonamide, a pyrazole, and an oxazole (and a related thiazole and imidazole)—

would provide a suitable molecular scaffold for the other three components typically found in selective antiestrogens—the phenol, the second aromatic unit, and the basic side chain—so that these new structural classes would also have selective antiestrogenic activity. The unique feature of these new core structures is that, unlike antiestrogens prepared up to now, they can be prepared by combinatorial chemistry means.


The first of the motifs, *motif A is an anti-bibenzyl system*, a structural subunit that is found in the potent estrogen hexestrol, as well as in the antiestrogen hydroxytamoxifen (Scheme 3). The structural analogs of this motif that we planned to explore, the diphenylcarboxamide and diphenylsulfonamide (Classes I and II), are well suited to three-component combinatorial solid phase synthesis methods (see below and Scheme 6). *Motif B is the homolog of the bibenzyl motif*, a substructure that is exemplified in the potent estrogen benzestrol and the selective estrogen raloxifene, but is otherwise largely undeveloped. We planned to explore several structural analogs of the homobibenzyl motif that are better suited for solid phase three-component combinatorial synthesis, benzylic homologs of the carboxamides and sulfonamides (Classes III and IV) and pyrazoles (Class V) (see below and Schemes 6 and 7). Finally, *Motif C, a syn-bibenzyl system* found in tamoxifen and centchroman, is the motivation for the three-component combinatorial synthesis of a series of heterocyclic analogs, oxazoles, thiazoles, and imidazoles (Class VI; see below and Scheme 8).

As we discuss below, we have made good progress evaluating the synthetic feasibility and ER binding affinity of members of all of these classes, as well as some others.

Results and Discussion


Synthesis of Class I: Diphenyl Carboxamides

We have followed the approach outlined in Scheme 6 in the original proposal to prepare a number of members of this class. Their structures are shown below, together with their binding affinity to ER. All of these compounds have been purified to analytical purity and fully characterized by spectroscopic means.



R	RBA
Et	0.062 %
Bu	0.042 %
<i>i</i> -Bu	0.02 %
<i>i</i> -Pr	0.009 %
Pentyl	0.007 %
Benzyl	0.089 %
CH(CH ₃)(CF ₃)	0.49 %
CH(C ₆ H ₅)(CF ₃)	10 %
CH(C ₆ H ₅)(CH ₃)	0.45 %

Estradiol = 100%




R	RBA
Et	0.62 %
Bu	1.3 %
<i>i</i> -Bu	1.5 %
<i>i</i> -Pr	0.83 %
Pentyl	1.7 %
Benzyl	0.15 %
CH(CH ₃)(CF ₃)	7.5 %
CH(CH ₃)(<i>i</i> -Pr)	4.6 %
CH(C ₆ H ₅)(CF ₃)	14 %
CH(C ₆ H ₅)(CH ₃)	2.5 %

It is interesting that the ER binding affinity of the members of this class cover a wide range, in a manner that is quite sensitive to relatively small changes in their structure. There are certain members that have quite high ER affinities.


One new finding that we made was that the thioamides have higher ER binding affinities than the carboxamides. In addition, fluorine substituents on the N-alkyl group greatly improve binding affinity. This is thought to be a combination of a lipophilic effect and an electronic effect on the syn-anti ratio of the amide geometric isomers, an issue that is being studied further.

Synthesis of Class II: Diphenyl Sulfonamides


We have followed the approach outlined in Scheme 6 in the original proposal to prepare a number of members of this class. Their structures are shown below, together with their binding affinity to ER. All of these compounds have been purified to analytical purity and fully characterized by spectroscopic means. As a class, however, these compounds generally have quite low ER binding affinity, and because of this they are not being studied further.



RBA = 0.23 %




RBA = 0.13 %



RBA = 0.053 %

Synthesis of Class III: Phenyl Benzylcarboxamides and Sulfonamides

We have followed the approach outlined in Scheme 6 in the original proposal to prepare a number of members of this class. Their structures are shown below, together with their binding affinity to ER. All of these compounds have been purified to analytical purity and fully characterized by spectroscopic means.




X	R ¹	R ²	RBA
O	Et	H	0.006 %
O	Et	Et	0.004 %
O	CH(CH ₃)(CF ₃)	CH ₃	0.01 % (1/1)
S	Et	H	0.020 %
S	Et	Et	0.089%

(Estradiol = 100%)

As indicated from the ER binding affinities this class appears to be unpromising at this time; however, we are continuing to analyze additional members containing the analogous substituents found in the higher binding analogs from Class I.

Synthesis of Class IV: Benzyl Phenylcarboxamides and Sulfonamides

We attempted to follow the approach outlined in Scheme 6 in the original proposal to prepare members of this class. However, we found that these compounds are unstable. An elimination reaction occurs whereby the amide unit is lost from the benzylic position of the *p*-hydroxybenzyl unit, with the presumed intermediacy of a quinone-methide, as illustrated below.

**Synthesis of Class V: Pyrazoles**

We have followed the approach outlined in Scheme 6 in the original proposal to prepare a number of members of this class. Their structures are shown below, together with their binding affinity to ER. All of these compounds have been purified to analytical purity and fully characterized by spectroscopic means.




Table 1. RBA Data for Pyrazoles


R ₂	R ₃	R ₄	% RBA
H	OH	H	0.009
H	OH	C ₆ H ₅	0.028
H	OH	C ₆ H ₅ CH ₂	<0.007
H	OH	p-HOC ₆ H ₄	0.059
C ₂ H ₅	OH	H	0.015
C ₂ H ₅	OH	C ₆ H ₅	14
C ₂ H ₅	OH	C ₆ H ₅ CH ₂	0.15 1.2 0.47
C ₂ H ₅	OH	p-HOC ₆ H ₄	2.4 11 22
CH ₃	OH	C ₆ H ₅	1.6
C ₂ H ₅	OH	CH ₂ CH ₂ OH	1.2
C ₂ H ₅	OH	(CH ₂) ₄ N((CH ₂) ₄)	0.013
C ₃ H ₇	OH	C ₆ H ₅	25
CH(CH ₃) ₂	OH	(CH ₂) ₄ N((CH ₂) ₄)	0.013

(Estradiol = 100%)

The binding properties of these compounds turned out to be very interesting as some of them have high affinity for the ER, and we have focused most of our attention on this class for the adaptation of syntheses to solid phase (see below).

Synthesis of Class VI: Oxazoles, Thiazoles and Imidazoles


We have followed the approach outlined in Scheme 6 in the original proposal to prepare a number of members of this class. Their structures are shown below, together with their binding affinity to ER. All of these compounds have been purified to analytical purity and fully characterized by spectroscopic means.



We have been able to make a number of conclusions based on our results so far. High affinity binding of these heterocycles seems to require four ring substituents. This means that the oxazoles and thiazoles, which can bear a maximum of three substituents, will probably never afford high ER binding affinity. The imidazoles, which can accommodate four substituents, have the highest affinities of the group, but, compared to the pyrazoles (Class V), they are relatively poor binders. Thus, in addition to being able to bear four substituents, the nature of the core heterocycle is important. Whether the difference in affinity between the pyrazoles and the imidazoles is the result of differing magnitudes or directions of dipole moments or other factors is not yet understood and is being investigated further by the preparation of additional isomers and analogs.

Adaptation of the Synthesis of Class V Agents (Pyrazoles) to Solid Phase Methods

Because they are both the most unusual structurally and have the highest ER binding affinities, we have selected the pyrazoles (Class V) as the ER ligands whose synthesis we wish to explore by solid phase methods. We have modified the approach shown in the original proposal for solid phase methods to prepare members of Class V, the pyrazoles. Because rather vigorous conditions were required to deprotect the protecting group on the second phenol substituent, we chose to attach the first phenol to the resin directly through a benzyl ether linkage (Merrifield), rather than through the more acid-labile and expensive Wang resin. Thus, the overall scheme for resin attachment³⁶⁻³⁷, pyrazole synthesis, and cleavage/deprotection are shown in the Scheme below:



We have spent considerable time working out conditions to ensure that the loading of the resin proceeds in optimal yield, and we have used IR and NMR spectroscopy on polymer-bound material to monitor all of the transformations³⁸⁻⁴⁰. We can follow the formation of the 1,3-diketone in the Claisen condensation using a ¹H NMR-MAS nanoprobe by observing the loss of the methylene proton signal α to the ketone and subsequent appearance of the methine signal at approx. 5 ppm (additional diagnostic chemical shifts are also prevalent). Formation of the pyrazole by reaction of hydrazine with dione can easily be followed by monitoring progressive disappearance of the carbonyl (C=O) band at 1670 cm⁻¹.

We have also worked to develop a consistent and efficient method to isolate the product pyrazoles free from inorganic contaminants and to characterize the level of residual synthetic precursors that are present in the sample. A standard, steep gradient elution of a reversed phase HPLC column proves to be a robust approach to characterizing product purity. Because the pyrazoles are uniformly fluorescent, we can use fluorescence detection to identify which of the eluted peaks is due to the pyrazole.

As we contemplate the synthesis of larger libraries, we have also evaluated various systems for the preparation of these pyrazoles on solid phase in a microtiter plate format. The Polyfiltronic plate system appears to work well, and withstands the solvent temperature combinations that are needed in the cyclization step of the pyrazole synthesis.

Progress in Relation to the Statement of Work

The complete three year Statement of Work, presented in the original proposal of July 1996, is shown below:

=====

ORIGINAL STATEMENT OF WORK

Project Period: July 1, 1997– June 30, 2000 (3 years)

Year 1

- Synthesis of representative members of Class I-VI ligands by solution phase methods.
- Isolate, purify, and fully characterize these members.
- Measure estrogen receptor binding affinity of representative members of Class I-VI ligands
- Begin to adapt solution phase syntheses to solid phase.

Year 2

- Complete adaptation of solution phase synthesis to solid phase.
- Isolate and fully characterize representative members produced by solid phase synthesis.
Determine yield and characterize impurities.
- Compare estrogen receptor binding of representative members of Class I-VI ligands prepared by solution vs solid phase.
- Begin synthesis of full Class I-VI libraries.
- Begin cell proliferation and cell-based transfection assays.

Year 3

- Complete synthesis of full Class I-VI libraries.
- Complete estrogen receptor assay of full libraries at two concentrations.
- Reassay the members with detectable estrogen receptor binding affinity by quantitative titration assay.
- Assay the members with high estrogen receptor binding affinity in the cell proliferation and cell-based transfection assays.
- Assay uterotrophic activity of the most promising members in rats.

=====

It is evident from the results presented in the preceeding sections that we have fulfilled all of the components of the Statement of Work for Year 1. In addition, we are already progressing on elements of the Statement of Work for Year 2, in that we have isolated and characterized representative members produced by solid phase synthesis, and we have determined yields and characterized impurities. We are beginning to make progress on the other work elements for Year 2.

CONCLUSIONS

From the results that we have achieved so far, we have identified several new series of non-steroidal estrogens that are adaptable to a combinatorial synthesis approach on solid phase. Some of the members of these series also have high affinity for the estrogen receptor. Thus, the project is progressing well along the lines that were originally envisioned in the initial proposal.

REFERENCES


1. Katzenellenbogen BS, Montano M, Le Goff P, Schodin DJ, Kraus WL, Bhardwaj B, Fujimoto N. Antiestrogens: Mechanisms and actions in target cells. *J. Steroid Biochem. Molec. Biol.* 1995; 53:387-393.
2. Katzenellenbogen BS, Fang H, Ince BA, Pakdel F, Reese JC, Wooge CH, Wrenn CK. Estrogen receptors: Ligand discrimination and antiestrogen action. *Breast Cancer Res. Treat.* 1993; 27:17-26.
3. Pasqualini JR, Katzenellenbogen BS. Hormone-Dependent Cancer. New York: Marcel Dekker, 1996.
4. Read LD, Katzenellenbogen BS. Characterization and regulation of estrogen and progesterone receptors in breast cancer. In: Dickson RB, Lippman ME, eds. Genes, Oncogenes, and Hormones: Advances in Cellular and Molecular Biology of Breast Cancer. Boston: Kluwer Academic Publishers, 1991; 277-299.
5. Chang JCN, A Review of Breast Cancer Chemoprevention. *Biomedicine & Pharmacotherapy* 1998; 52:133-136.
6. Jordan VC, Morrow M. Should clinicians be concerned about the carcinogenic potential of tamoxifen? *Eur. J. Cancer* 1994; 30A:1714-1721.
7. Katzenellenbogen BS. Antiestrogen resistance: Mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. *J. Natl. Cancer Inst.* 1991; 83:1434-1435.
8. Davidson NE. Hormone-replacement therapy—breast versus heart versus bone. *N. Engl. J. Med.* 1995; 332:1638-1639.
9. Nique F, Van de Velde P, Bremaud J, Hardy M, Philibert D, Teutsch G. 11β-Amidoalkoxyphenyl estradiols, a new series of pure antiestrogens. *J. Steroid Biochem. Molec. Biol.* 1994; 50:21-29.
10. Nicholson RI, Gee JMW, Francis AB, Manning DL, Wakeling AE, Katzenellenbogen BS. Observations arising from the use of pure antioestrogens on oestrogen-responsive (MCF-7) and oestrogen growth-independent (K3) human breast cancer cells. *Endocrine Related Cancer* 1995; 2:1-7.
11. Wakeling AE, Bowler J. Biology and mode of action of pure antiestrogens. *J Steroid Biochem* 1988; 30:141-147.
12. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. *Cancer Res* 1991; 51:3867-3873.
13. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. *J. Natl. Cancer Inst.* 1995; 87:746-750.
14. Howell A, DeFriend D, Robertson J, Blamey R, Walton P. Response to a specific antiestrogen (ICI 182780) in tamoxifen-resistant breast cancer. *Lancet* 1995; 345:29-30.
15. Katzenellenbogen BS. Estrogen receptors: Bioactivities and interactions with cell signaling pathways. *Biol. Reprod.* 1996; 54:287-293.
16. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. *Mol. Endocrinol.* 1996; 10:119-131.

17. Montano MM, Ekena KE, Krueger KD, Keller AL, Katzenellenbogen BS. Human estrogen receptor ligand activity inversion mutants: Receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. *Mol. Endocrinol.* 1996; 10:230-242.
18. Montano MM, Müller V, Trobaugh A, Katzenellenbogen BS. The carboxy-terminal F domain of the human estrogen receptor: Role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. *Mol Endocrinol* 1995; 9:814-825.
19. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. *Mol Endocrinol* 1994; 8:21-30.
20. Berry M, Metzger D, Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. *EMBO J.* 1990; 9:2811-2818.
21. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. *Mol Endocrinol* 1995; 9:659-669.
22. Yang NN, Hardikar S, Kim J. Raloxifene, an anti-estrogen, simulates the effects of estrogen on inhibiting bone resorption through regulating TGF β -3 expression in bone. *J. Bone Miner. Res.* 1993; 8 (Suppl 1):S118.
23. Yang NN, Bryant HU, Hardikar S, Sato M, Galvin RJS, Glasebrook AL, Termine JD. Estrogen and raloxifene stimulate transforming growth factor- β 3 gene expression in rat bone: A potential mechanism for estrogen- or raloxifene-mediated bone maintenance. *Endocrinology* 1996; 137:2075-2084.
24. Sato M, Glasebrook AL, Bryant HU. Raloxifene: A selective estrogen receptor modulator. *J Bone Miner Met* 1994; 12 (Suppl 2):S9-S20.
25. Sato M, Rippey MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. *FASEB J.* 1996; 10:905-912.
26. von Angerer E. The Estrogen Receptor as a Target for Rational Drug Design. Austin: R.G. Landes Company, 1995.
27. Gordon EM, Barrett RW, Dower WJ, Fodor SPA, Gallop MA. Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions. *J. Med. Chem.* 1994; 37:1385-1401.
28. Gallop MA, Barrett RW, Dower WJ, Fodor SPA, Gordon EM. Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries. *J. Med. Chem.* 1994; 37:1233-1251.
29. Geysen HM, Houghten RA, Kauffman S, Lebl M, Moos WH, Pavia MR, Szostak JW. Molecular diversity comes of age! *Molecular Diversity* 1995; 1:2-3.
30. Murphy MM, Schullek JR, Gordon EM, Gallop MA. Combinatorial organic synthesis of highly functionalized pyrrolidines: Identification of a potent angiotensin converting enzyme inhibitor from a mercaptoacyl proline library. *J. Am. Chem. Soc.* 1995; 117:7029-7030.
31. Terrett NK, Bojanic D, Brown D, Bungay PJ, Gardner M, Gordon DW, Mayers CJ, Steele J. The combinatorial synthesis of a 30,752-compound library: Discovery of SAR around the endothelin antagonist, FR-139,317. *Bioorg. Med. Chem. Lett.* 1995; 5:917-922.
32. Boojamra CG, Burow KM, Ellman JA. An expedient and high-yielding method for the solid-phase synthesis of diverse 1,4-benzodiazepine-2,5-diones. *J. Org. Chem.* 1995; 60:5742-5743.
33. Goff DA, Zuckermann RN. Solid-phase synthesis of defined 1,4-benzodiazepine-2,5-dione mixtures. *J. Org. Chem.* 1995; 60:5744-5745.
34. Plunkett MJ, Ellman JA. Solid-phase synthesis of structurally diverse 1,4-benzodiazepine derivatives using the Stille coupling reaction. *J. Am. Chem. Soc.* 1995; 117:3306-3307.


35. DeWitt SH, Kiely JS, Stankovic CJ, Schroeder MC, Cody DMR, Pavia MR. "Diversomers": An approach to nonpeptide, nonoligomeric chemical diversity. *Proc. Natl. Acad. Sci. U.S.A.* 1993; 90:6909-6913.
36. Krchnák V, Flegelová Z, Weichsel AS, Lebl M. Polymer-supported Mitsunobu ether formation and its use in combinatorial chemistry. *Tetrahedron Lett.* 1995; 36:6193-6196.
37. Marzinik AL, Felder ER. Solid support synthesis of highly functionalized pyrazoles and isoxazoles; scaffolds for molecular diversity. *Tetrahedron Lett.* 1996; 37:1003-1006.
38. Yan B, Kumaravel G, Anjaria H, Wu A, Petter RC, Jewell CF, Jr., Wareing JR. Infrared spectrum of a single resin bead for real-time monitoring of solid-phase reactions. *J. Org. Chem.* 1995; 60:5736-5738.
39. Fitch WL, Detre G, Holmes CP. High-resolution ^1H NMR in solid-phase organic synthesis. *J. Org. Chem.* 1994; 59:7955-7956.
40. Giralt E, Rizo J, Pedroso E. Application of gel-phase ^{13}C -NMR to monitor solid phase peptide synthesis. *Tetrahedron* 1984; 40:4141-4152.

Scheme 1. Estrogens, Pure Antiestrogens, and Selective Antiestrogens – From the Original Proposal


Estrogens:




Pure Antiestrogens:


















Selective Antiestrogens:



Scheme 2. Structural Components of Selective Antiestrogens – From the Original Proposal




Scheme 3. Structural Motifs for Estrogen Receptor Ligands
and Their Combinatorial Analogs – From the Original Proposal




Estrogen Receptor Ligand	Structural Motif	Combinatorial Analog (Class)
 Hexestrol	 Motif A. <i>anti</i> -Bibenzyl	I. Diphenyl Carboxamides 
 Hydroxytamoxifen		II. Diphenyl Sulfonamides 
 Benzestrol	 Motif B. <i>Homobibenzyl</i>	III. Phenyl Benzylcarboxamides & Sulfonamides  (or SO ₂ in place of CO)
 Raloxifene		IV. Benzyl Phenylcarboxamides & Sulfonamides  (or SO ₂ in place of CO)
		V. Pyrazoles 
 Hydroxy-Tamoxifen	 Motif C. <i>syn</i> -Bibenzyl	VI. Oxazoles, Thiazoles, and Imidazoles  (X = O, S, NR)
 Centchroman		

**Scheme 5. Protection or Attachment of the Phenolic Amine Component (Element 1)
– From the Original Proposal**


Element 1 Solution phase synthesis [protection]



Element 1 Solid phase synthesis [attachment]





*In the following Schemes, the protecting group or polymer linker unit is designated



Scheme 7. Combinatorial Synthesis of Pyrazoles (Class V) – From the Original Proposal

Combinatorial Elements





DEPARTMENT OF THE ARMY

US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

26 Aug 02

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB274369
ADB256383
ADB264003
ADB274462
ADB266221
ADB274470
ADB266221
ADB274464
ADB259044
ADB258808
ADB266026
ADB274658
ADB258831
ADB266077
ADB274348
ADB274273
ADB258193
ADB274516
ADB259018
ADB231912
ADB244626
ADB256677
ADB229447
ADB240218
ADB258619
ADB259398
ADB275140
ADB240473
ADB254579
ADB277040
ADB249647
ADB275184
ADB259035
ADB244774
ADB258195
ADB244675
ADB257208
ADB267108
ADB244889
ADB257384
ADB270660
ADB274493
ADB261527
ADB274286
ADB274269
ADB274592
ADB274604

ADB274596
ADB258952
ADB265976
ADB274350
ADB274346
ADB257408
ADB274474
ADB260285
ADB274568
ADB266076
ADB274441
ADB253499
ADB274406
ADB262090
ADB261103
ADB274372